Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

Download PDF Copy

Sep 22 2010

NewsGuard 100/100 Score

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

Teva previously filed a separate lawsuit against Mylan in October 2009 for infringement of multiple patents, including all seven Orange Book patents, covering the chemical composition of COPAXONE®, pharmaceutical compositions containing it, methods of using it and processes for making it. Those patents expire in May 2014 and September 2015. No trial date is scheduled.

Source:

Teva Pharmaceutical Industries Ltd.

Posted in: Medical Patent News | Pharmaceutical News

Tags: Biotechnology, Generic Drug, Medicaid, Medicare, Pharmaceuticals, Protonix

Comments (0)

Download PDF Copy

Suggested Reading

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

Study highlights disparities in stroke burden across regions

Study highlights disparities in stroke burden across regions

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Urine RNA analysis shows promise for detecting genitourinary diseases

Urine RNA analysis shows promise for detecting genitourinary diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Early RSV vaccination in pregnancy provides best protection for newborns